

Table SI. Chemotherapy treatment patterns for the treatment-naïve cohort.

A, First line, n (%)	
Treatment	N (%)
Carboplatin/Paclitaxel	79 (36.1)
Cisplatin/Pemetrexed/Zoledronic acid	71 (32.4)
Cisplatin/Pemetrexed	30 (13.7)
Carboplatin/ Gemcitabine	10 (4.6)
Carboplatin/Paclitaxel/Bevacizumab	9 (4.1)
Cisplatin/Etoposide	5 (2.3)
Carboplatin/Pemetrexed	5 (2.3)
Platinum/Pemetrexed	5 (2.3)
Docetaxel	3 (1.4)
Cisplatin/Gemcitabine	2 (0.9)
Total	219
B, Second line, n (%)	
Treatment	N (%)
Docetaxel	8 (33.3)
Carboplatin/Pemetrexed	4 (16.7)
Carboplatin	3 (12.5)
Carboplatin/Paclitaxel	2 (8.3)
Pemetrexed	2 (8.3)
Carboplatin/Gemcitabine	1 (4.2)
Cisplatin/Pemetrexed/Zoledronic acid	1 (4.2)
Cisplatin/Etoposide	1 (4.2)
Cisplatin/Pemetrexed	1 (4.2)
Platinum/Pemetrexed	1 (4.2)
Total	24

Table SII. Immunotherapy treatment patterns for the treatment-naïve cohort.

A, First line, n (%)	
Treatment	N (%)
Pembrolizumab	11 (68.8)
Nivolumab + Ipilimumab	4 (25.0)
Atezolizumab	1 (6.2)
Total	16
B, Second line, n (%)	
Treatment	N (%)
Pembrolizumab	15 (51.7)
Atezolizumab	8 (27.6)
Nivolumab	6 (20.7)
Total	29